Market Overview:
The global duodenal ulcer treatment market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of duodenal ulcers, rising awareness about available treatments, and technological advancements in the field of duodenal ulcer treatment. Based on type, the global duodenal ulcer treatment market can be segmented into antibiotics, proton pump inhibitors (PPIs), antacids, potassium-competitive acid blockers (P-CABs), H2-antagonists, and ulcer protective drugs. PPIs are expected to dominate this market due to their high efficacy and safety profile. Based on application, the global duodenal ulcer treatment market can be segmented into adult and elderly patients. The adult patient segment is expected to account for a larger share of this market than the elderly patient segment due to an increase in life expectancy across regions worldwide.
Product Definition:
Duodenal ulcer is a lesion that affects the duodenum, which is the first part of the small intestine. Treatment for duodenal ulcers typically involves antibiotics to clear any infection, as well as medications to reduce stomach acid. Surgery may also be necessary in some cases. The importance of treatment for duodenal ulcers is that they can cause pain and irritation in the digestive system, as well as complications such as bleeding and perforation.
Antibiotics:
Antibiotics Market is expected to grow at a significant rate over the forecast period owing to rising incidences of bacterial infections coupled with increasing geriatric population base. According to CDC, around 1.7 million people die every year due to antibiotic-resistant bacteria. This factor is projected to drive market growth over the next seven years.
Proton Pump Inhibitors:
Proton pump inhibitors (PPIs) are a group of drugs that decrease the production of stomach acid. The most common type of ulcer treatment using PPI is duodenal ulcer, which is a peptic ulcer in the innermost layer of the stomach. Proton pump inhibitors can be used to treat other types as well, such as gastric and esophageal or “gastric” ulcers.
Application Insights:
Based on application, the global duodenal ulcer treatment market is segmented into adult and elderly patients. In 2017, the adult population constituted for more than half of the overall patient base. This can be attributed to increasing prevalence of chronic diseases such as cancer and diabetes which increase susceptibility to peptic ulcers. As per ULCA-accordion, in 2018 approximately 1 out of 5 people above 60 years have some form of gastric or duodenal ulcer disease while about 1 out of 10 above 75 years are affected by these disorders globally.
The elderly population is expected to witness significant growth over the forecast period owing to rising geriatric population across various regions coupled with growing life expectancy at birth rate globally (see figure below). According Ulcerative Colitis Foundation (ULCA), Inc.
Regional Analysis:
North America dominated the global market in 2017, with a revenue share of over 40.0%. This is attributed to the high prevalence of duodenal ulcers and increased adoption of lifestyle changes such as smoking, alcohol consumption, and unhealthy dietary patterns. Moreover, increasing healthcare expenditure by governments coupled with rising awareness about early diagnosis is anticipated to fuel growth during the forecast period.
Asia Pacific region is expected to witness lucrative growth over the forecast period owing to factors such as growing geriatric population base; improving economic conditions leading to an increase in disposable income; and rapid urbanization resulting from migration from rural areas. In addition, unmet clinical needs for treatment options are fueling demand for PUD therapy drugs in this region which will further propel market growth during the estimated time span 8 . The presence of large untapped opportunities along with rapidly developing economies present throughout Asia Pacific including China & India are some key regional growth drivers 9-11 .
Growth Factors:
- Increasing incidence of duodenal ulcers
- Growing awareness about duodenal ulcer treatment options
- Rising demand for minimally invasive procedures
- Technological advancements in duodenal ulcer treatment devices
- increasing prevalence of Helicobacter pylori infection
Scope Of The Report
Report Attributes
Report Details
Report Title
Duodenal Ulcer Treatment Market Research Report
By Type
Antibiotics, Proton Pump Inhibitors, Antacids, Potassium-Competitive Acid Blockers (P-CAB), H2-Antagonist, Ulcer Protective Drugs, Surgery
By Application
Adult, Elderly
By Companies
GlaxoSmithKline, Pfizer, Abbott Laboratories, Merck, Nihon Pharmaceuticals, Novartis, Bristol Meyer Squibb, AstraZeneca, Takeda, Ei Sai
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
219
Number of Tables & Figures
154
Customization Available
Yes, the report can be customized as per your need.
Global Duodenal Ulcer Treatment Market Report Segments:
The global Duodenal Ulcer Treatment market is segmented on the basis of:
Types
Antibiotics, Proton Pump Inhibitors, Antacids, Potassium-Competitive Acid Blockers (P-CAB), H2-Antagonist, Ulcer Protective Drugs, Surgery
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Adult, Elderly
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GlaxoSmithKline
- Pfizer
- Abbott Laboratories
- Merck
- Nihon Pharmaceuticals
- Novartis
- Bristol Meyer Squibb
- AstraZeneca
- Takeda
- Ei Sai
Highlights of The Duodenal Ulcer Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Antibiotics
- Proton Pump Inhibitors
- Antacids
- Potassium-Competitive Acid Blockers (P-CAB)
- H2-Antagonist
- Ulcer Protective Drugs
- Surgery
- By Application:
- Adult
- Elderly
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Duodenal Ulcer Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Duodenal ulcer treatment is a combination of medications and lifestyle changes that are aimed at healing the ulcer. Treatment may include antibiotics, pain relief medication, antacids, and dietary changes.
Some of the key players operating in the duodenal ulcer treatment market are GlaxoSmithKline, Pfizer, Abbott Laboratories, Merck, Nihon Pharmaceuticals, Novartis, Bristol Meyer Squibb, AstraZeneca, Takeda, Ei Sai.
The duodenal ulcer treatment market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Duodenal Ulcer Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Duodenal Ulcer Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Duodenal Ulcer Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Duodenal Ulcer Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Duodenal Ulcer Treatment Market Size & Forecast, 2018-2028
4.5.1 Duodenal Ulcer Treatment Market Size and Y-o-Y Growth
4.5.2 Duodenal Ulcer Treatment Market Absolute $ Opportunity
Chapter 5 Global Duodenal Ulcer Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Duodenal Ulcer Treatment Market Size Forecast by Type
5.2.1 Antibiotics
5.2.2 Proton Pump Inhibitors
5.2.3 Antacids
5.2.4 Potassium-Competitive Acid Blockers (P-CAB)
5.2.5 H2-Antagonist
5.2.6 Ulcer Protective Drugs
5.2.7 Surgery
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Duodenal Ulcer Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Duodenal Ulcer Treatment Market Size Forecast by Applications
6.2.1 Adult
6.2.2 Elderly
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Duodenal Ulcer Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Duodenal Ulcer Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Duodenal Ulcer Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Duodenal Ulcer Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Duodenal Ulcer Treatment Market Size Forecast by Type
9.6.1 Antibiotics
9.6.2 Proton Pump Inhibitors
9.6.3 Antacids
9.6.4 Potassium-Competitive Acid Blockers (P-CAB)
9.6.5 H2-Antagonist
9.6.6 Ulcer Protective Drugs
9.6.7 Surgery
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Duodenal Ulcer Treatment Market Size Forecast by Applications
9.10.1 Adult
9.10.2 Elderly
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Duodenal Ulcer Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Duodenal Ulcer Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Duodenal Ulcer Treatment Market Size Forecast by Type
10.6.1 Antibiotics
10.6.2 Proton Pump Inhibitors
10.6.3 Antacids
10.6.4 Potassium-Competitive Acid Blockers (P-CAB)
10.6.5 H2-Antagonist
10.6.6 Ulcer Protective Drugs
10.6.7 Surgery
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Duodenal Ulcer Treatment Market Size Forecast by Applications
10.10.1 Adult
10.10.2 Elderly
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Duodenal Ulcer Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Duodenal Ulcer Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Duodenal Ulcer Treatment Market Size Forecast by Type
11.6.1 Antibiotics
11.6.2 Proton Pump Inhibitors
11.6.3 Antacids
11.6.4 Potassium-Competitive Acid Blockers (P-CAB)
11.6.5 H2-Antagonist
11.6.6 Ulcer Protective Drugs
11.6.7 Surgery
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Duodenal Ulcer Treatment Market Size Forecast by Applications
11.10.1 Adult
11.10.2 Elderly
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Duodenal Ulcer Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Duodenal Ulcer Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Duodenal Ulcer Treatment Market Size Forecast by Type
12.6.1 Antibiotics
12.6.2 Proton Pump Inhibitors
12.6.3 Antacids
12.6.4 Potassium-Competitive Acid Blockers (P-CAB)
12.6.5 H2-Antagonist
12.6.6 Ulcer Protective Drugs
12.6.7 Surgery
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Duodenal Ulcer Treatment Market Size Forecast by Applications
12.10.1 Adult
12.10.2 Elderly
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Duodenal Ulcer Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Duodenal Ulcer Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Duodenal Ulcer Treatment Market Size Forecast by Type
13.6.1 Antibiotics
13.6.2 Proton Pump Inhibitors
13.6.3 Antacids
13.6.4 Potassium-Competitive Acid Blockers (P-CAB)
13.6.5 H2-Antagonist
13.6.6 Ulcer Protective Drugs
13.6.7 Surgery
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Duodenal Ulcer Treatment Market Size Forecast by Applications
13.10.1 Adult
13.10.2 Elderly
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Duodenal Ulcer Treatment Market: Competitive Dashboard
14.2 Global Duodenal Ulcer Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 GlaxoSmithKline
14.3.2 Pfizer
14.3.3 Abbott Laboratories
14.3.4 Merck
14.3.5 Nihon Pharmaceuticals
14.3.6 Novartis
14.3.7 Bristol Meyer Squibb
14.3.8 AstraZeneca
14.3.9 Takeda
14.3.10 Ei Sai
